Simoctocog alfa (Nuwiq, Vihuma)

概览

Simoctocog alfa is an antihemorrhagic agent used for the treatment and prophylaxis of bleeding in patients of all ages with haemophilia A (congenital factor VIII deficiency).

作用机制

Haemophilia A is a sex-linked hereditary disorder of blood coagulation due to decreased levels of factor VIII:C. The disorder is associated with episodes of recurrent bleeding and profuse bleeding into joints, muscles or internal organs, either spontaneously or as results of accidental or surgical trauma . Factor VIII circulates in the plasma as a hemostatically active protein complex that consists of factor VIII and a large carrier protein von Willebrand factor via a non-covalent binding interaction. This protein complex remains inactive until the coagulation cascade is activated which in turn activates factor VIII to be released from factor VIII/von Willebrand factor complex. Activated factor VIII acts as a cofactor for factor IX-mediated conversion of factor X to activated factor X. Activated factor X is critical in converting prothrombin into thrombin and sequentially, thrombin converts fibrinogen to fibrin for the formation of a blood clot . Simoctocog alfa is an antihemophilic factor that circulates as part of a protein complex with coagulant activity. As a replacement therapy, simoctocog alfa serves to restore the normal levels of factor VIII and allow effective blood clot formation in patients with haemophilia A.

适应症

Simoctocog alfa is a recombinant antihemophilic factor [blood coagulation factor VIII (Factor VIII) indicated in adults and children with Hemophilia A for the on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes. It is not indicated for the treatment of von Willebrand Disease.

• Bleeding caused by Hemophilia A